[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371510-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371510-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","perspectives-of-targeting-autophagy-as-an-adjuvant-to-anti-pd-1pd-l1-therapy-for-colorectal-cancer-treatment","Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment","","Colorectal cancer (CRC) remains a major global health burden, with rising incidence and mortality despite surgery, chemotherapy, and radiotherapy. Immune checkpoint inhibitors, particularly anti-PD-1/PD-L1, can generate durable responses by leveraging neoantigens produced from DNA replication errors, which are more prominent in MSI-H/dMMR than in MSS/pMMR. A key limitation is that anti-PD-1/PD-L1 benefit is largely restricted to MSI-H/dMMR. This review examines autophagy as a determinant of tumor immune responses and evaluates how autophagy modulation may enable combination strategies with anti-PD-1/PD-L1 to broaden efficacy in CRC treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/perspectives-of-targeting-autophagy-as-an-adjuvant-to-anti-pd-1pd-l1-therapy-for-colorectal-cancer-treatment/371510/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/perspectives-of-targeting-autophagy-as-an-adjuvant-to-anti-pd-1pd-l1-therapy-for-colorectal-cancer-treatment/371510.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are anti-PD-1/PD-L1 immune checkpoint inhibitors effective in some colorectal cancer patients?","Question",{"text":63,"@type":64},"Their benefit is linked to the abundance of neoantigens generated by DNA replication errors, which promote stronger immune responses. This effect is typically more pronounced in MSI-H/dMMR tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limits the use of anti-PD-1/PD-L1 therapy in colorectal cancer?",{"text":68,"@type":64},"Anti-PD-1/PD-L1 effectiveness is largely confined to MSI-H/dMMR cases. MSS/pMMR patients have different immune characteristics, reducing the impact of checkpoint blockade.",{"name":70,"@type":61,"acceptedAnswer":71},"How does autophagy modulation relate to anti-PD-1/PD-L1 treatment in this review?",{"text":72,"@type":64},"The review highlights autophagy as a potential determinant of tumor immune response and a factor shaping the tumor immune microenvironment. It also explores autophagy modulators combined with anti-PD-1/PD-L1 as an adjuvant approach to widen treatment scope.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371510,1790463797,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nPerspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment  \nNasrah ALKhemeiri 1, Sahar Eljack 2,3 and Maha Mohamed Saber-Ayad 1,2,4,5, *  \nAcademic Editor: Maria Condello  \nReceived: 13 February 2025  \nRevised: 7 May 2025  \nAccepted: 12 May 2025  \nPublished: 20 May 2025  \nCitation: ALKhemeiri, N.; Eljack, S.; Saber-Ayad, M.M. Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment. Cells 2025, 14, 745. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells14100745](10.3390/cells14100745)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 College of Graduate Studies, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates  \n2 Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates; [sfadlalla@sharjah.ac.ae](sfadlalla@sharjah.ac.ae)  \n3 Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Wad Madani 21111, Sudan  \n4 Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates  \n5 Department of Pharmacology, Faculty of Medicine, Cairo University, Cairo 12211, Egypt  \n* [Correspondence: msaber@sharjah.ac.ae](Correspondence: msaber@sharjah.ac.ae)  \nAbstract: Colorectal cancer (CRC) is the third most common cancer in the world, with increasing incidence and mortality rates. Standard conventional treatments for CRC are surgery, chemotherapy, and radiotherapy. Recently, immunotherapy has been introduced as a promising alternative to CRC treatment that utilizes patients’ immune system to combat cancer cells. The beneficial effect of immune checkpoint inhibitors, specifically anti-PD-1/ PD-L1, has been ascribed to the abundance of DNA replication errors that result in the formation of neoantigens. Such neoantigens serve as distinct flags that amplify the immune response when checkpoint inhibitors (ICIs) are administered. DNA replication errors in CRC patients are expressed as two statuses: the first is the deficient mismatch repair (MSI-H/dMMR) with a higher overall immune response and survival rate than the second status of patients with proficient mismatch repair (MSS/pMMR) . There is a limitation to using anti-PD-1/PD-L1 as it is only confined to MSI-H/dMMR, where there is an abundance of T-cell inhibitory ligands (PD-L1) . This calls for investigating new therapeutic interventions to widen the scope of ICIs’ role in the treatment of CRC. Autophagy modulation provides a good example. Autophagy is a cellular process that plays a crucial role in maintaining cellular homeostasis and has been studied for its impact on tumor development, progression, and response to treatment. In this review, we aim to highlight autophagy as a potential determinant in tumor immune response and to study the impact of autophagy on the tumor immune microenvironment. Moreover, we aim to investigate the value of a combination of anti-PD-1/PD-L1 agents with autophagy modulators as an adjuvant therapeutic approach for CRC treatment.  \nKeywords: autophagy; colorectal cancer; immunotherapy; tumor immune microenvironment; anti-PD-1/PD-L1; microsatellite instability; immune checkpoint inhibitors; therapeutic resistance  \n1. Introduction  \nColorectal cancer (CRC) is the third most prevalent cancer type [1,2] . It currently accounts for 9.6% of all malignant tumors and is the most prevalent type of cancer in the digestive system [2,3] . Its current incidence and mortality in men are 10.4% and 9.2%, and in women, 8.9% and 9.4%, respectively [2] . In the upcoming years, it is anticipated to surpass the overall mo","cbCaimV8Pczu5jlw","https://ap.wps.com/l/cbCaimV8Pczu5jlw","pdf",1433414,27,"English","# Introduction","[{\"question\":\"Why are anti-PD-1/PD-L1 immune checkpoint inhibitors effective in some colorectal cancer patients?\",\"answer\":\"Their benefit is linked to the abundance of neoantigens generated by DNA replication errors, which promote stronger immune responses. This effect is typically more pronounced in MSI-H/dMMR tumors.\"},{\"question\":\"What limits the use of anti-PD-1/PD-L1 therapy in colorectal cancer?\",\"answer\":\"Anti-PD-1/PD-L1 effectiveness is largely confined to MSI-H/dMMR cases. MSS/pMMR patients have different immune characteristics, reducing the impact of checkpoint blockade.\"},{\"question\":\"How does autophagy modulation relate to anti-PD-1/PD-L1 treatment in this review?\",\"answer\":\"The review highlights autophagy as a potential determinant of tumor immune response and a factor shaping the tumor immune microenvironment. It also explores autophagy modulators combined with anti-PD-1/PD-L1 as an adjuvant approach to widen treatment scope.\"}]","Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment | PDF",1790192236,68,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78a1a19cf21cc864beebe00befa0405f.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4d7be8408419e2adcc818dcbbefc907.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/214be54cb80a171106a596d03033c92f.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70494164ffb15303273b4f59a395c8fe.webp",980,1385]